TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents
June 2nd, 2016
Here we present a protocol for screening of a heptamer-type sgRNA library for potential therapeutic drugs against blood cancers.
The overall goal of this screening is to find potential therapeutic drugs against blood cancers.Begin this procedure by selecting a subset of Heptamer sequences.The sequences can be random, or designed to target specific cellular RNAs.To target specific cellular RNAs, use an appropriate computer program to find hairpin structures resembling the T-arm in a target RNA.Select complementary seven-nucleotide sequences immediately downstream of the hairpin.Using the phosphoramidite method on the controlled pore glass, or CPG support, synthesize each of the selected Heptamers as a fully 2-prime O-methylated, 5-prime and 3-prime phosphorylated RNA with the DNA-RNA synthesizer.Leave the 5-prime terminal DMT protecting group on in the last cycle of the synthesis.After completion of the last cycle, transfer the CPG with the synthesized oligonucleotide from the column to a glass vial with a teflon-lined screw cap.Add 1mL of 29%ammonium hydroxide and incubate the tube at 55
View the full transcript and gain access to thousands of scientific videos
Overview
This article presents a protocol for screening a heptamer-type sgRNA library aimed at identifying potential therapeutic drugs for blood cancers.
Key Study Components
Area of Science
- Neuroscience
- Oncology
- Genetic Engineering
Background
- Blood cancers pose significant treatment challenges.
- Novel therapeutic approaches are needed to improve patient outcomes.
- sgRNA libraries can facilitate targeted gene editing.
- This study focuses on a specific type of sgRNA for therapeutic screening.
Purpose of Study
- To develop a protocol for screening sgRNA libraries.
- To identify potential drug candidates for blood cancers.
- To enhance the understanding of gene editing in therapeutic contexts.
Methods Used
- Design and synthesis of heptamer-type sgRNA libraries.
- Screening protocols for evaluating therapeutic efficacy.
- Analysis of gene editing outcomes.
- Validation of potential drug candidates through experimental assays.
Main Results
- Identification of promising sgRNAs with therapeutic potential.
- Demonstration of effective screening methodology.
- Insights into the role of sgRNA in blood cancer treatment.
- Recommendations for further research and development.
Conclusions
- The protocol provides a valuable tool for drug discovery.
- Heptamer-type sgRNAs show promise in targeting blood cancers.
- Future studies should focus on clinical applications and efficacy.
Frequently Asked Questions
Executive Industry Relevance
This protocol enables systematic screening of heptamer-type sgRNA libraries to identify RNA-directed therapeutic candidates for blood cancers, supporting early-stage target validation and mechanistic de-risking. By leveraging tRNase ZL-mediated gene silencing, the approach offers a transfection-independent modality for inducing apoptosis in malignant cells, aligning with discovery-stage efforts to expand therapeutic modalities beyond small molecules or antibodies. The scalable library design (16,384 heptamers) supports high-throughput evaluation, providing a path to prioritize sgRNAs with demonstrated efficacy in myeloma and leukemia models for further preclinical development.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of RNA targets via tRNase ZL-dependent silencing to validate therapeutic hypotheses in blood cancer models.
- Operational Value: Uses chemically modified, cell-permeable sgRNAs that bypass transfection reagents, simplifying assay setup in suspension cancer cell lines.
- Predictive Value: Identifies sgRNAs that induce apoptosis, providing functional readouts linked to target engagement and phenotypic outcome.
Screening & Assay Development
- Assay Readiness: Supports preparation of standardized viability and apoptosis assays using flow cytometry to quantify sgRNA effects on cell survival.
- Scalability: Designed for screening large sgRNA libraries (e.g., 16,384 heptamers) to enable systematic structure-activity relationship mapping.
- Reproducibility: Employs synthetic, fully 2'-O-methylated, 5'- and 3'-phosphorylated sgRNAs to ensure batch consistency and reduce variability in screening outcomes.
Translational & Preclinical Research
- Disease Relevance: Focuses on human myeloma and leukemia cell lines, providing a disease-contextualized system for target validation in hematologic malignancies.
- Mechanistic De-risking: Links sgRNA activity to apoptosis induction, offering insight into mechanism of action prior to lead optimization.
- Translational Continuity: Supports progression from hit identification to further evaluation of effective sgRNAs using orthogonal validation methods like flow cytometry.
Pipeline & Workflow Integration
The method fits within the early discovery continuum, supporting target hypothesis testing and lead identification for blood cancer therapeutics by generating functionally validated sgRNA hits that can inform downstream medicinal chemistry or nucleic acid therapeutic design.
- Discovery Biology: Enables target validation through phenotypic screening of sgRNA libraries in relevant cancer models, clarifying RNA targets associated with apoptosis.
- Screening: Produces quantitative viability and apoptosis data to support assay standardization and hit selection in high-throughput formats.
- Analytics: Generates functional readouts (viability loss, apoptosis induction) that enable comparison of sgRNA activity and prioritization of candidates.
- Translational Research: Connects initial screening hits to further mechanistic evaluation in preclinical models using apoptosis and flow cytometry assays.
- Enterprise Reuse: Establishes a reusable platform for screening nucleic acid-based therapeutics across multiple cancer types and target classes.
Operational & Enterprise Impact
- Scientific Value: Provides mechanistic insight into RNA-targeted apoptosis, reducing ambiguity in target validation for blood cancer therapies.
- Operational Value: Standardizes sgRNA synthesis and screening workflow, enhancing reproducibility and cross-team collaboration.
- Strategic Value: Improves go/no-go decisions by identifying apoptosis-inducing sgRNAs early, reducing investment in non-functional candidates.
- Portfolio Impact: Enables risk-adjusted prioritization of sgRNA hits based on efficacy in leukemia and myeloma models, supporting efficient resource allocation.
Implementation Considerations
- Requires expertise in RNA synthesis using phosphoramidite chemistry and HPLC purification of modified oligonucleotides.
- Dependent on access to DNA-RNA synthesizers and controlled pore glass (CPG) support for sgRNA production.
- Necessitates standardized cell culture and viability/apoptosis assay protocols across screening teams.
- Requires adaptation for different cancer models beyond myeloma and leukemia to assess broader applicability.
- Limited by the need to screen large libraries to identify hits, as only ~20/156 sgRNAs showed activity in the pilot screen.
